{"transactions":[{"id":1100152,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock Purchase Warrant (Right to Buy)","published_at":"2025-06-27T17:05:19.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2976,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, the Reporting Person elected to receive $2.95 per warrant, an amount equal to the Black Scholes Value (as defined in the Merger Agreement) for the warrants reported herein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, the Reporting Person elected to receive $2.95 per warrant, an amount equal to the Black Scholes Value (as defined in the Merger Agreement) for the warrants reported herein."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the Merger Agreement, the Reporting Person elected to receive $2.95 per warrant, an amount equal to the Black Scholes Value (as defined in the Merger Agreement) for the warrants reported herein."}],"balance_after":0,"derivative":{"exercise_price":7.46,"underlying":"Common Stock","underlying_shares":2976},"source":{"system":"sec-edgar","filing":"0000950170-25-091015","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000095017025091015/ownership.xml","form_type":"4"}},{"id":1100151,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2025-06-27T17:05:19.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1350000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":1,"underlying":"Common Stock","underlying_shares":1350000},"source":{"system":"sec-edgar","filing":"0000950170-25-091015","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000095017025091015/ownership.xml","form_type":"4"}},{"id":1100150,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2025-06-27T17:05:19.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":990000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":2.01,"underlying":"Common Stock","underlying_shares":990000},"source":{"system":"sec-edgar","filing":"0000950170-25-091015","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000095017025091015/ownership.xml","form_type":"4"}},{"id":1100149,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2025-06-27T17:05:19.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":249000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":1.3,"underlying":"Common Stock","underlying_shares":249000},"source":{"system":"sec-edgar","filing":"0000950170-25-091015","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000095017025091015/ownership.xml","form_type":"4"}},{"id":1100148,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2025-06-27T17:05:19.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1312500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":1.36,"underlying":"Common Stock","underlying_shares":1312500},"source":{"system":"sec-edgar","filing":"0000950170-25-091015","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000095017025091015/ownership.xml","form_type":"4"}},{"id":1100147,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2025-06-27T17:05:19.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":1.48,"underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000950170-25-091015","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000095017025091015/ownership.xml","form_type":"4"}},{"id":1100146,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2025-06-27T17:05:19.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."}],"balance_after":0,"derivative":{"exercise_price":13.1,"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-25-091015","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000095017025091015/ownership.xml","form_type":"4"}},{"id":1100145,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2025-06-27T17:05:19.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":160000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":2.6,"underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0000950170-25-091015","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000095017025091015/ownership.xml","form_type":"4"}},{"id":1100144,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2025-06-27T17:05:19.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":90000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."}],"balance_after":0,"derivative":{"exercise_price":13.1,"underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0000950170-25-091015","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000095017025091015/ownership.xml","form_type":"4"}},{"id":1100143,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2025-06-27T17:05:19.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":6.4,"underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000950170-25-091015","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000095017025091015/ownership.xml","form_type":"4"}},{"id":1100142,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2025-06-27T17:05:19.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."}],"balance_after":0,"derivative":{"exercise_price":9.5,"underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0000950170-25-091015","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000095017025091015/ownership.xml","form_type":"4"}},{"id":1100141,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2025-06-27T17:05:19.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."}],"balance_after":0,"derivative":{"exercise_price":9.5,"underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0000950170-25-091015","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000095017025091015/ownership.xml","form_type":"4"}},{"id":1100140,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-06-27T17:05:19.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":571558,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, (i) each Share was converted into the right to receive the Offer Price and (ii) each performance stock unit (\"PSU\") was canceled and converted into the right to receive (A) an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of Shares underlying such PSU immediately prior to the Effective Time by (y) the Closing Amount plus (B) one CVR with respect to each such Share subject to such PSU immediately prior to the Effective Time. The 280,750 PSUs reported herein were unintentionally omitted from previous Form 4 filings made by the Reporting Person following the achievement of the performance-based vesting conditions applicable thereto."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-091015","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000095017025091015/ownership.xml","form_type":"4"}},{"id":1289409,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-31T17:00:10.000Z","date":"2025-01-30","kind":"grant","planned":false,"acquired":true,"shares":1350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option commenced vesting on January 1, 2025 and will vest ratably on a monthly basis over a 48 month period subject to the reporting person's continuous service to Regulus through each such vesting date."}],"balance_after":1350000,"derivative":{"exercise_price":1,"expiration_date":"2035-01-29","underlying":"Common Stock","underlying_shares":1350000},"source":{"system":"sec-edgar","filing":"0000950170-25-011853","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000095017025011853/ownership.xml","form_type":"4"}},{"id":1289408,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-01-31T17:00:10.000Z","date":"2025-01-30","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":1.0852,"value":54260.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average purchase price for the transaction reported was $1.0852, and the range of prices were between $1.065 and $1.0897. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each price will be provided."}],"balance_after":260808,"source":{"system":"sec-edgar","filing":"0000950170-25-011853","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000095017025011853/ownership.xml","form_type":"4"}},{"id":1302549,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-01-15T17:00:05.000Z","date":"2025-01-14","kind":"sale","planned":true,"acquired":false,"shares":11764,"price":1.2632,"value":14860.2848,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) which commenced vesting on January 12, 2024. These sales are made pursuant to an existing 10b5-1 plan under which the Reporting Person has irrevocably elected to satisfy the tax obligations through this sale and do not represent discretionary trades by the Reporting Person."}],"balance_after":210808,"source":{"system":"sec-edgar","filing":"0000950170-25-005883","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000095017025005883/ownership.xml","form_type":"4"}},{"id":1302548,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-01-15T17:00:05.000Z","date":"2025-01-13","kind":"sale","planned":true,"acquired":false,"shares":115290,"price":1.2632,"value":145634.328,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) which commenced vesting on January 9, 2025.  These sales are made pursuant to an existing 10b5-1 plan under which the Reporting Person has irrevocably elected to satisfy the tax obligations through this sale and do not represent discretionary trades by the Reporting Person."}],"balance_after":222572,"source":{"system":"sec-edgar","filing":"0000950170-25-005883","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000095017025005883/ownership.xml","form_type":"4"}},{"id":1305111,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-01-10T17:00:11.000Z","date":"2025-01-09","kind":"grant","planned":false,"acquired":true,"shares":62000,"price":1.3,"value":80600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On January 12, 2024, the reporting person was granted Restricted Stock Units (RSUs). The RSUs only vest upon achievement of a specified performance-based milestone.  The performance criteria were met resulting in immediate vesting of 50% of the shares subject to the grant.  The remaining 50% vest on the one year anniversary of the vesting commencement date, subject to the reporting person's Continuous Service to Regulus."}],"balance_after":337862,"source":{"system":"sec-edgar","filing":"0000950170-25-004274","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000095017025004274/ownership.xml","form_type":"4"}},{"id":1305110,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-01-10T17:00:11.000Z","date":"2025-01-09","kind":"grant","planned":false,"acquired":true,"shares":218750,"price":1.36,"value":297500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 10, 2023, the reporting person was granted Restricted Stock Units (RSUs). The RSUs only vest upon achievement of a specified performance-based milestone.  The performance criteria were met resulting in immediate vesting of 50% of the shares subject to the grant.  The remaining 50% vest on the one year anniversary of the vesting commencement date, subject to the reporting person's Continuous Service to Regulus."}],"balance_after":275862,"source":{"system":"sec-edgar","filing":"0000950170-25-004274","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000095017025004274/ownership.xml","form_type":"4"}},{"id":1507086,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-21T16:21:26.000Z","date":"2024-05-20","kind":"grant","planned":false,"acquired":true,"shares":990000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest ratably on a monthly basis over a 48 month period subject to the reporting person's continuous service to Regulus through each such vesting date."}],"balance_after":990000,"derivative":{"exercise_price":2.01,"expiration_date":"2034-05-19","underlying":"Common Stock","underlying_shares":990000},"source":{"system":"sec-edgar","filing":"0000950170-24-062920","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000095017024062920/ownership.xml","form_type":"4"}},{"id":1676293,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-18T20:22:50.000Z","date":"2024-01-18","kind":"sale","planned":false,"acquired":false,"shares":14580,"price":1.1906,"value":17358.948,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person.  These sales are made pursuant to an existing 10b5-1 plan under which the Reporting Person has irrevocably elected to satisfy the tax obligations through this sale and do not represent discretionary trades by the Reporting Person."}],"balance_after":57112,"source":{"system":"sec-edgar","filing":"0001209191-24-001873","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919124001873/doc4.xml","form_type":"4"}},{"id":1677789,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-17T17:16:21.000Z","date":"2024-01-12","kind":"grant","planned":false,"acquired":true,"shares":249000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option will vest ratably on a monthly basis over a 48 month period subject to the reporting person's continuous service to Regulus through each such vesting date."}],"balance_after":249000,"derivative":{"exercise_price":1.3,"expiration_date":"2034-01-11","underlying":"Common Stock","underlying_shares":249000},"source":{"system":"sec-edgar","filing":"0001209191-24-001778","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919124001778/doc4.xml","form_type":"4"}},{"id":1677788,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-17T17:16:21.000Z","date":"2024-01-12","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On January 11, 2023, the reporting person was granted Restricted Stock Units (RSUs).  The RSUs only vested upon achievement of a performance-based milestone. The performance criteria were met resulting in immediate vesting of 50% of the shares subject to the grant. The remaining 50% vest on the one year anniversary of the vesting commencement date, subject to the reporting person's Continuous Service to Regulus."}],"balance_after":71692,"source":{"system":"sec-edgar","filing":"0001209191-24-001778","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919124001778/doc4.xml","form_type":"4"}},{"id":1808489,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-14T16:17:12.000Z","date":"2023-08-10","kind":"grant","planned":false,"acquired":true,"shares":1312500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest ratably on a monthly basis over a 48 month period subject to the reporting person's continuous service to Regulus through each such vesting date."}],"balance_after":1312500,"derivative":{"exercise_price":1.36,"expiration_date":"2033-08-09","underlying":"Common Stock","underlying_shares":1312500},"source":{"system":"sec-edgar","filing":"0001209191-23-045624","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919123045624/doc4.xml","form_type":"4"}},{"id":1881031,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-05-23T17:18:43.000Z","date":"2023-05-18","kind":"exercise","planned":false,"acquired":false,"shares":8733,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of Issuer Common Stock. The RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of Issuer Common Stock. The RSUs have no expiration date."}],"balance_after":0,"derivative":{"exercise_date":"2023-05-18","underlying":"Common Stock","underlying_shares":8733},"source":{"system":"sec-edgar","filing":"0001600620-23-000021","document":"wk-form4_1684876715.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000160062023000021/wk-form4_1684876715.xml","form_type":"4"}},{"id":1881030,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-23T17:18:43.000Z","date":"2023-05-19","kind":"sale","planned":false,"acquired":false,"shares":272,"price":10.58,"value":2877.76,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of RSUs."}],"balance_after":11961,"source":{"system":"sec-edgar","filing":"0001600620-23-000021","document":"wk-form4_1684876715.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000160062023000021/wk-form4_1684876715.xml","form_type":"4"}},{"id":1881029,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-23T17:18:43.000Z","date":"2023-05-18","kind":"exercise","planned":false,"acquired":true,"shares":8733,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of Issuer Common Stock. The RSUs have no expiration date."}],"balance_after":12233,"source":{"system":"sec-edgar","filing":"0001600620-23-000021","document":"wk-form4_1684876715.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000160062023000021/wk-form4_1684876715.xml","form_type":"4"}},{"id":2053698,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-17T16:11:19.000Z","date":"2023-01-11","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest ratably on a monthly basis over a 48 month period subject to the reporting person's continuous service to Regulus through each such vesting date."}],"balance_after":100000,"derivative":{"exercise_price":1.48,"expiration_date":"2033-01-10","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-23-003520","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919123003520/doc4.xml","form_type":"4"}},{"id":2261736,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-20T16:07:27.000Z","date":"2022-05-18","kind":"grant","acquired":true,"shares":14612,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in twelve equal monthly installments commencing on June 18, 2022."}],"balance_after":14612,"derivative":{"exercise_price":11.45,"expiration_date":"2032-05-18","underlying":"Common Stock","underlying_shares":14612},"source":{"system":"sec-edgar","filing":"0001628280-22-015028","document":"wf-form4_165307722519945.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000162828022015028/wf-form4_165307722519945.xml","form_type":"4"}},{"id":2261735,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2022-05-20T16:07:27.000Z","date":"2022-05-18","kind":"grant","acquired":true,"shares":8733,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest and be delivered to the Reporting Person one year from date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest and be delivered to the Reporting Person one year from date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest and be delivered to the Reporting Person one year from date of grant."}],"balance_after":8733,"derivative":{"underlying":"Common Shares","underlying_shares":8733},"source":{"system":"sec-edgar","filing":"0001628280-22-015028","document":"wf-form4_165307722519945.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000162828022015028/wf-form4_165307722519945.xml","form_type":"4"}},{"id":2274721,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-11T16:54:02.000Z","date":"2022-05-10","kind":"grant","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests only upon achievement of a performance-based milestone. The performance criteria were met, resulting in vesting of the option. Upon achievement of the milestone and verification of same by the Company's Compensation Committee, one hundred percent of the shares immediately vested."}],"balance_after":300000,"derivative":{"exercise_price":1.31,"expiration_date":"2030-01-20","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001209191-22-028337","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919122028337/doc4.xml","form_type":"4"}},{"id":2425156,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-26T16:13:34.000Z","date":"2022-01-12","kind":"grant","acquired":true,"shares":1600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest ratably on a monthly basis over a 48 month period subject to the reporting person's continuous service to Regulus through each such vesting date."}],"balance_after":1600000,"derivative":{"exercise_price":0.26,"expiration_date":"2032-01-11","underlying":"Common Stock","underlying_shares":1600000},"source":{"system":"sec-edgar","filing":"0001209191-22-005061","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919122005061/doc4.xml","form_type":"4"}},{"id":2425155,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-01-26T16:13:34.000Z","date":"2022-01-26","kind":"purchase","acquired":true,"shares":100000,"price":0.2152,"value":21520.0,"ownership":{"direct":true},"balance_after":417006,"source":{"system":"sec-edgar","filing":"0001209191-22-005061","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919122005061/doc4.xml","form_type":"4"}},{"id":2448877,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-01-04T16:17:04.000Z","date":"2022-01-03","kind":"exercise","acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option are fully vested and immediately exercisable. They vested in twelve equal monthly installments from the grant date."}],"balance_after":10000,"derivative":{"exercise_price":5.08,"expiration_date":"2028-02-08","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001628280-22-000182","document":"wf-form4_164133098196321.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000162828022000182/wf-form4_164133098196321.xml","form_type":"4"}},{"id":2448876,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-04T16:17:04.000Z","date":"2022-01-03","kind":"sale","acquired":false,"shares":634,"price":23.29,"value":14765.86,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":3500,"source":{"system":"sec-edgar","filing":"0001628280-22-000182","document":"wf-form4_164133098196321.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000162828022000182/wf-form4_164133098196321.xml","form_type":"4"}},{"id":2448875,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-04T16:17:04.000Z","date":"2022-01-03","kind":"sale","acquired":false,"shares":39366,"price":22.58,"value":888884.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $22.27 to $23.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":4134,"source":{"system":"sec-edgar","filing":"0001628280-22-000182","document":"wf-form4_164133098196321.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000162828022000182/wf-form4_164133098196321.xml","form_type":"4"}},{"id":2448874,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-04T16:17:04.000Z","date":"2022-01-03","kind":"exercise","acquired":true,"shares":40000,"price":5.08,"value":203200.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date."}],"balance_after":43500,"source":{"system":"sec-edgar","filing":"0001628280-22-000182","document":"wf-form4_164133098196321.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000162828022000182/wf-form4_164133098196321.xml","form_type":"4"}},{"id":2666211,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-16T21:23:21.000Z","date":"2021-06-14","kind":"grant","acquired":true,"shares":31347,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twelve equal monthly installments commencing on July 14, 2021."}],"balance_after":31347,"derivative":{"exercise_price":12.86,"expiration_date":"2031-06-14","underlying":"Common Shares","underlying_shares":31347},"source":{"system":"sec-edgar","filing":"0001628280-21-012389","document":"wf-form4_162389298391433.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000162828021012389/wf-form4_162389298391433.xml","form_type":"4"}},{"id":2670098,"issuer":{"id":12518,"kind":"organization","name":"Zosano Pharma Corp","symbol":"ZSAN"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-14T20:31:44.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date and (ii) immediately prior to the annual meeting in 2022 of the Issuer's stockholders, assuming continuous service through  such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":0.9318,"expiration_date":"2031-06-09","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001567619-21-012083","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000156761921012083/doc1.xml","form_type":"4"}},{"id":2670097,"issuer":{"id":12518,"kind":"organization","name":"Zosano Pharma Corp","symbol":"ZSAN"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-14T20:31:44.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units which vest in a single installment on the earlier of (i) the first anniversary of the grant date and (ii) immediately prior to the annual meeting in 2022 of the Issuer's stockholders, assuming continuous service through such vesting date."}],"balance_after":22500,"source":{"system":"sec-edgar","filing":"0001567619-21-012083","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000156761921012083/doc1.xml","form_type":"4"}},{"id":2710243,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-05-17T19:13:47.000Z","date":"2021-05-17","kind":"sale","acquired":false,"shares":4186,"price":0.89,"value":3725.54,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person on 11/12/2018.  These sales are made pursuant to an existing 10b5-1 plan under which the Reporting Person has irrevocably elected to satisfy the tax obligations through this sale and do not represent discretionary trades by the Reporting Person."}],"balance_after":316292,"source":{"system":"sec-edgar","filing":"0001209191-21-033297","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919121033297/doc4.xml","form_type":"4"}},{"id":2746970,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Class A-2 Convertible Preferred Stock","published_at":"2021-04-16T16:12:40.000Z","date":"2021-04-14","kind":"exercise","acquired":true,"shares":7585,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"PACIFIC PREMIER TRUST OBO JOSEPH P. HAGAN IRA"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Class A-2 Convertible Preferred Stock have no expiration date and are convertible at any time at the election of the holder into shares of Common Stock without payment of further consideration.  Each share of Class A-2 Convertible Preferred Stock converts into 10 shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Class A-2 Convertible Preferred Stock have no expiration date and are convertible at any time at the election of the holder into shares of Common Stock without payment of further consideration.  Each share of Class A-2 Convertible Preferred Stock converts into 10 shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Class A-2 Convertible Preferred Stock have no expiration date and are convertible at any time at the election of the holder into shares of Common Stock without payment of further consideration.  Each share of Class A-2 Convertible Preferred Stock converts into 10 shares of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":7585},"source":{"system":"sec-edgar","filing":"0001209191-21-026952","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919121026952/doc4.xml","form_type":"4"}},{"id":2746969,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-04-16T16:12:40.000Z","date":"2021-04-14","kind":"exercise","acquired":true,"shares":75850,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Class A-2 Convertible Preferred Stock have no expiration date and are convertible at any time at the election of the holder into shares of Common Stock without payment of further consideration.  Each share of Class A-2 Convertible Preferred Stock converts into 10 shares of Common Stock."}],"balance_after":320478,"source":{"system":"sec-edgar","filing":"0001209191-21-026952","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919121026952/doc4.xml","form_type":"4"}},{"id":2746968,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-04-16T16:11:19.000Z","date":"2021-02-16","kind":"sale","acquired":false,"shares":4144,"price":1.72,"value":7127.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person on 11/12/2018.  These sales are made pursuant to an existing 10b5-1 plan under which the Reporting Person has irrevocably elected to satisfy the tax obligations through this sale and do not represent discretionary trades by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This Form 4 is being amended to correct the number of securities beneficially owned following the reported transaction."}],"balance_after":244628,"source":{"system":"sec-edgar","filing":"0001209191-21-026951","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919121026951/doc4a.xml","form_type":"4/A","original_submission_date":"2021-02-17"}},{"id":2854425,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-02-17T17:23:07.000Z","date":"2021-02-16","kind":"sale","acquired":false,"shares":4144,"price":1.72,"value":7127.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person on 11/12/2018.  These sales are made pursuant to an existing 10b5-1 plan under which the Reporting Person has irrevocably elected to satisfy the tax obligations through this sale and do not represent discretionary trades by the Reporting Person."}],"balance_after":485756,"source":{"system":"sec-edgar","filing":"0001209191-21-011377","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919121011377/doc4.xml","form_type":"4"}},{"id":2876601,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-05T17:01:15.000Z","date":"2021-02-04","kind":"grant","acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option commenced vesting on January 1, 2021 and will vest ratably on a monthly basis over a 48 month period subject to the reporting person's continuous service to Regulus through each such vesting date."}],"balance_after":600000,"derivative":{"exercise_price":1.59,"expiration_date":"2031-02-04","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001209191-21-008170","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919121008170/doc4.xml","form_type":"4"}},{"id":2955097,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock Purchase Warrant (Right to Buy)","published_at":"2020-12-07T16:22:33.000Z","date":"2020-12-04","kind":"grant","acquired":true,"shares":29760,"price":0.125,"value":3720.0,"ownership":{"direct":false,"nature":"Securities purchased through an affiliated investment entity"},"balance_after":29760,"derivative":{"exercise_price":0.7464,"exercise_date":"2020-12-04","expiration_date":"2025-12-04","underlying":"Common Stock","underlying_shares":29760},"source":{"system":"sec-edgar","filing":"0001209191-20-061940","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919120061940/doc4.xml","form_type":"4"}},{"id":2955096,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-12-07T16:22:33.000Z","date":"2020-12-04","kind":"grant","acquired":true,"shares":39680,"price":0.6301,"value":25002.368,"ownership":{"direct":false,"nature":"Securities purchased through an affiliated investment entity"},"balance_after":225674,"source":{"system":"sec-edgar","filing":"0001209191-20-061940","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919120061940/doc4.xml","form_type":"4"}},{"id":2975137,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-11-18T16:09:52.000Z","date":"2020-11-16","kind":"sale","acquired":false,"shares":6094,"price":0.5211,"value":3175.5834,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person on 11/12/2018.  These sales are made pursuant to an existing 10b5-1 plan under which the Reporting Person has irrevocably elected to satisfy the tax obligations through this sale and do not represent discretionary trades by the Reporting Person."}],"balance_after":215994,"source":{"system":"sec-edgar","filing":"0001209191-20-059050","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919120059050/doc4.xml","form_type":"4"}},{"id":3055857,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-08-17T20:22:11.000Z","date":"2020-08-14","kind":"sale","acquired":false,"shares":4245,"price":0.6049,"value":2567.8005,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person on 11/12/2018.  These sales are made pursuant to an existing 10b5-1 plan under which the Reporting Person has irrevocably elected to satisfy the tax obligations through this sale and do not represent discretionary trades by the Reporting Person."}],"balance_after":222088,"source":{"system":"sec-edgar","filing":"0001209191-20-047033","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919120047033/doc4.xml","form_type":"4"}},{"id":3097513,"issuer":{"id":12518,"kind":"organization","name":"Zosano Pharma Corp","symbol":"ZSAN"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true}}],"security":"Common Stock","published_at":"2020-06-29T21:54:06.000Z","date":"2020-06-25","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents restricted stock units which vest in a single installment on the first anniversary of June 3, 2020, subject to the Reporting Person's continued service to the Issuer on the vesting date."}],"balance_after":7500,"source":{"system":"sec-edgar","filing":"0001140361-20-015095","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000114036120015095/form4.xml","form_type":"4"}},{"id":3120290,"issuer":{"id":12518,"kind":"organization","name":"Zosano Pharma Corp","symbol":"ZSAN"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-05T17:05:09.000Z","date":"2020-06-03","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest on the first anniversary of the date of grant."}],"balance_after":15000,"derivative":{"exercise_price":1.01,"expiration_date":"2030-06-02","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001567619-20-011805","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000156761920011805/doc1.xml","form_type":"4"}},{"id":3145435,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-05-18T16:28:07.000Z","date":"2020-05-15","kind":"sale","acquired":false,"shares":4426,"price":0.6267,"value":2773.7742,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person on 11/12/2018.  These sales are made pursuant to an existing 10b5-1 plan under which the Reporting Person has irrevocably elected to satisfy the tax obligations through this sale and do not represent discretionary trades by the Reporting Person."}],"balance_after":226333,"source":{"system":"sec-edgar","filing":"0001209191-20-030089","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919120030089/doc4.xml","form_type":"4"}},{"id":3263074,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-02-19T18:09:57.000Z","date":"2020-02-18","kind":"sale","acquired":false,"shares":4324,"price":0.8304,"value":3590.6496,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person on 11/12/2018.  These sales are made pursuant to an existing 10b5-1 plan under which the Reporting Person has irrevocably elected to satisfy the tax obligations through this sale and do not represent discretionary trades by the Reporting Person."}],"balance_after":230759,"source":{"system":"sec-edgar","filing":"0001209191-20-010754","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919120010754/doc4.xml","form_type":"4"}},{"id":3302937,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-24T16:13:12.000Z","date":"2020-01-22","kind":"grant","acquired":true,"shares":900000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest ratably on a monthly basis over a 48 month period subject to the reporting person's continuous service to Regulus through each such vesting date."}],"balance_after":900000,"derivative":{"exercise_price":1.31,"expiration_date":"2030-01-21","underlying":"Common Stock","underlying_shares":900000},"source":{"system":"sec-edgar","filing":"0001209191-20-004813","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919120004813/doc4.xml","form_type":"4"}},{"id":3322831,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-01-03T16:07:13.000Z","date":"2020-01-02","kind":"sale","acquired":false,"shares":8345,"price":0.9667,"value":8067.1115,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person on 2/5/2019. These sales are made pursuant to an existing 10b5-1 plan under which the Reporting Person has irrevocably elected to satisfy the tax obligations through this sale and do not represent discretionary trades by the Reporting Person."}],"balance_after":235083,"source":{"system":"sec-edgar","filing":"0001209191-20-000785","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919120000785/doc4.xml","form_type":"4"}},{"id":3331224,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock Purchase Warrant (Right to Buy)","published_at":"2019-12-26T08:50:19.000Z","date":"2019-12-24","kind":"grant","acquired":true,"shares":75850,"price":0.125,"value":9481.25,"ownership":{"direct":false,"nature":"PENSCO TRUST CO OBO JOSEPH HAGAN IRA"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The securities were acquired from the issuer pursuant to a Securities Purchase Agreement dated May 3, 2019.  The Securities Purchase Agreement and the issuance of the securities thereunder were approved by the Issuer's Board of Directors and an independent committee thereof."}],"balance_after":75850,"derivative":{"exercise_price":0.666,"exercise_date":"2019-12-24","expiration_date":"2024-12-24","underlying":"Common Stock","underlying_shares":75850},"source":{"system":"sec-edgar","filing":"0001209191-19-061855","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919119061855/doc4.xml","form_type":"4"}},{"id":3331223,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Class A-2 Convertible Preferred Stock","published_at":"2019-12-26T08:50:19.000Z","date":"2019-12-24","kind":"grant","acquired":true,"shares":7585,"price":6.66,"value":50516.1,"ownership":{"direct":false,"nature":"PENSCO TRUST CO OBO JOSEPH HAGAN IRA"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Class A-2 Convertible Preferred Stock have no expiration date and are convertible at any time at the election of the holder into shares of Common Stock without payment of further consideration.  Each share of Class A-2 Convertible Preferred Stock converts into 10 shares of Common Stock."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The securities were acquired from the issuer pursuant to a Securities Purchase Agreement dated May 3, 2019.  The Securities Purchase Agreement and the issuance of the securities thereunder were approved by the Issuer's Board of Directors and an independent committee thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Class A-2 Convertible Preferred Stock have no expiration date and are convertible at any time at the election of the holder into shares of Common Stock without payment of further consideration.  Each share of Class A-2 Convertible Preferred Stock converts into 10 shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Class A-2 Convertible Preferred Stock have no expiration date and are convertible at any time at the election of the holder into shares of Common Stock without payment of further consideration.  Each share of Class A-2 Convertible Preferred Stock converts into 10 shares of Common Stock."}],"balance_after":7585,"derivative":{"underlying":"Common Stock","underlying_shares":75850},"source":{"system":"sec-edgar","filing":"0001209191-19-061855","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919119061855/doc4.xml","form_type":"4"}},{"id":3369829,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-11-15T17:36:57.000Z","date":"2019-11-14","kind":"sale","acquired":false,"shares":5838,"price":0.64,"value":3736.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person on 10/12/2018.  These sales are made pursuant to an existing 10b5-1 plan under which the Reporting Person has irrevocably elected to satisfy the tax obligations through this sale and do not represent discretionary trades by the Reporting Person."}],"balance_after":243428,"source":{"system":"sec-edgar","filing":"0001209191-19-056799","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919119056799/doc4.xml","form_type":"4"}},{"id":3393621,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-15T16:43:27.000Z","date":"2019-10-10","kind":"grant","acquired":true,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest ratably on a monthly basis over a 48 month period subject to the reporting person's continuous service to Regulus through each such vesting date."}],"balance_after":1000000,"derivative":{"exercise_price":0.64,"expiration_date":"2029-10-09","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001209191-19-053164","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919119053164/doc4.xml","form_type":"4"}},{"id":3401006,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-10-02T18:17:43.000Z","date":"2019-10-01","kind":"sale","acquired":false,"shares":8743,"price":0.6827,"value":5968.8461,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person on 2/5/2019. These sales are made pursuant to an existing 10b5-1 plan under which the Reporting Person has irrevocably elected to satisfy the tax obligations through this sale and do not represent discretionary trades by the Reporting Person."}],"balance_after":249266,"source":{"system":"sec-edgar","filing":"0001209191-19-051910","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919119051910/doc4.xml","form_type":"4"}},{"id":3436111,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-08-16T16:17:23.000Z","date":"2019-08-15","kind":"sale","acquired":false,"shares":4375,"price":0.5506,"value":2408.875,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person on 2/5/2019. These sales are made pursuant to an existing 10b5-1 plan under which the Reporting Person has irrevocably elected to satisfy the tax obligations through this sale and do not represent discretionary trades by the Reporting Person."}],"balance_after":258009,"source":{"system":"sec-edgar","filing":"0001209191-19-046314","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919119046314/doc4.xml","form_type":"4"}},{"id":3459168,"issuer":{"id":12518,"kind":"organization","name":"Zosano Pharma Corp","symbol":"ZSAN"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-18T16:08:33.000Z","date":"2019-01-02","kind":"grant","acquired":true,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest on the first anniversary of the date of grant."}],"balance_after":1500,"derivative":{"exercise_price":2.34,"expiration_date":"2029-01-02","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001567619-19-014981","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000156761919014981/doc1.xml","form_type":"4"}},{"id":3471148,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-07-02T17:42:57.000Z","date":"2019-07-01","kind":"sale","acquired":false,"shares":5783,"price":1.3115,"value":7584.4045,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person on 2/5/2019. These sales are made pursuant to an existing 10b5-1 plan under which the Reporting Person has irrevocably elected to satisfy the tax obligations through this sale and do not represent discretionary trades by the Reporting Person."}],"balance_after":262384,"source":{"system":"sec-edgar","filing":"0001209191-19-040504","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919119040504/doc4.xml","form_type":"4"}},{"id":3516827,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock Purchase Warrant (Right to Buy)","published_at":"2019-05-21T16:42:59.000Z","date":"2019-05-07","kind":"grant","acquired":true,"shares":33194,"price":0.125,"value":4149.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 is being amended to correct the transaction code. The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated May 3, 2019 with a closing date of May 7, 2019.  The Securities Purchase Agreement and the issuance of the securities thereunder was approved by the Issuer's Board of Directors and an independent committee thereof."}],"balance_after":33194,"derivative":{"exercise_price":1.08,"exercise_date":"2019-05-07","expiration_date":"2024-05-07","underlying":"Common Stock","underlying_shares":33194},"source":{"system":"sec-edgar","filing":"0001209191-19-031763","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919119031763/doc4a.xml","form_type":"4/A","original_submission_date":"2019-05-08"}},{"id":3516826,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-05-21T16:42:59.000Z","date":"2019-05-07","kind":"grant","acquired":true,"shares":33194,"price":1.08,"value":35849.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 is being amended to correct the transaction code. The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated May 3, 2019 with a closing date of May 7, 2019.  The Securities Purchase Agreement and the issuance of the securities thereunder was approved by the Issuer's Board of Directors and an independent committee thereof."}],"balance_after":64542,"source":{"system":"sec-edgar","filing":"0001209191-19-031763","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919119031763/doc4a.xml","form_type":"4/A","original_submission_date":"2019-05-08"}},{"id":3523817,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-16T17:25:41.000Z","date":"2019-05-14","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On February 5, 2019, the reporting person was granted an option to purchase the number of shares of common stock set forth in Box 5. The option vests only upon the achievement of a performance-based milestone. The performance criteria were met, resulting in vesting of the option. Upon achievement of the milestone, 50% of the options subject to the milestone immediately vest, with the remaining options vesting in 24 equal monthly installments following the vesting commencement date."}],"balance_after":10000,"derivative":{"exercise_price":0.95,"exercise_date":"2019-05-14","expiration_date":"2029-02-04","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-19-030512","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919119030512/doc4.xml","form_type":"4"}},{"id":3523816,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-05-16T17:25:41.000Z","date":"2019-05-16","kind":"sale","acquired":false,"shares":39352,"price":1.2189,"value":47966.1528,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person on 5/14/2019.  These sales are made pursuant to an existing 10b5-1 plan under which the Reporting Person has irrevocably elected to satisfy the tax obligations through this sale and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $1.1946 to $1.2210 inclusive.  The reporting person undertakes to provide to RGLS, any security holder of RGLS, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":268167,"source":{"system":"sec-edgar","filing":"0001209191-19-030512","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919119030512/doc4.xml","form_type":"4"}},{"id":3523815,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-05-16T17:25:41.000Z","date":"2019-05-14","kind":"grant","acquired":true,"shares":188385,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On November 11, 2018, the reporting person was granted Restricted Stock Units in the Company's tender offer. The RSUs vest only upon the achievement of a performance-based milestone. The performance criteria were met, resulting in vesting of the RSUs. Upon achievement of the milestone, 50% of the RSU subject to the milestone immediately vest, with the remaining RSUs vesting quarterly in the 24 months following the vesting commencement date."}],"balance_after":307519,"source":{"system":"sec-edgar","filing":"0001209191-19-030512","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919119030512/doc4.xml","form_type":"4"}},{"id":3535105,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock Purchase Warrant (Right to Buy)","published_at":"2019-05-08T17:15:57.000Z","date":"2019-05-07","kind":"purchase","acquired":true,"shares":33194,"price":0.125,"value":4149.25,"ownership":{"direct":true},"balance_after":33194,"derivative":{"exercise_price":1.08,"exercise_date":"2019-05-07","expiration_date":"2024-05-07","underlying":"Common Stock","underlying_shares":33194},"source":{"system":"sec-edgar","filing":"0001209191-19-028281","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919119028281/doc4.xml","form_type":"4"}},{"id":3535104,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-05-08T17:15:57.000Z","date":"2019-05-07","kind":"purchase","acquired":true,"shares":33194,"price":1.08,"value":35849.52,"ownership":{"direct":true},"balance_after":64542,"source":{"system":"sec-edgar","filing":"0001209191-19-028281","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919119028281/doc4.xml","form_type":"4"}},{"id":3564656,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-04-03T16:31:20.000Z","date":"2019-04-01","kind":"sale","acquired":false,"shares":5842,"price":0.981,"value":5731.002,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares of common stock under an existing 10b5-1 Plan to cover tax withholding obligations incurred in connection with the vesting of the restricted stock unit award received by the Reporting Person on 2/5/2019."}],"balance_after":31348,"source":{"system":"sec-edgar","filing":"0001209191-19-023136","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919119023136/doc4.xml","form_type":"4"}},{"id":3672231,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-06T16:51:39.000Z","date":"2019-02-05","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option will vest ratably on a monthly basis over a 48 month period subject to the reporting person's continuous service to Regulus through each such vesting date."}],"balance_after":65000,"derivative":{"exercise_price":0.95,"expiration_date":"2029-02-04","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001209191-19-007777","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919119007777/doc4.xml","form_type":"4"}},{"id":3672230,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-02-06T16:51:39.000Z","date":"2019-02-05","kind":"grant","acquired":true,"shares":65000,"price":0.95,"value":61750.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted Stock Units which vest ratably on a quarterly basis such that the grant is fully vested on December 31, 2019, subject to the reporting person's continuous service to Regulus through each such vesting date."}],"balance_after":84148,"source":{"system":"sec-edgar","filing":"0001209191-19-007777","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919119007777/doc4.xml","form_type":"4"}},{"id":3910675,"issuer":{"id":12518,"kind":"organization","name":"Zosano Pharma Corp","symbol":"ZSAN"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-01T19:06:58.000Z","date":"2018-05-31","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option grant was approved by the compensation committee of the Company's board of directors on April 16, 2018, subject to stockholder approval of an amendment to the stock option plan under which the option was granted. The Company's stockholders approved the plan amendment on May 31, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the stock option vest in equal monthly installments over a four-year period, beginning on May 16, 2018, so that all shares shall have vested on April 16, 2022."}],"balance_after":25000,"derivative":{"exercise_price":4.24,"expiration_date":"2028-04-16","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001587221-18-000027","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000158722118000027/edgar.xml","form_type":"4"}},{"id":3923985,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-21T16:40:44.000Z","date":"2018-05-17","kind":"grant","acquired":true,"shares":725000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in forty-eight equal monthly installments, such that the option will be fully vested four years from the date of grant, subject to the Reporting Person's continuous service to us."}],"balance_after":725000,"derivative":{"exercise_price":0.71,"expiration_date":"2028-05-16","underlying":"Common Stock","underlying_shares":725000},"source":{"system":"sec-edgar","filing":"0001209191-18-031892","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919118031892/doc4.xml","form_type":"4"}},{"id":4019931,"issuer":{"id":12518,"kind":"organization","name":"Zosano Pharma Corp","symbol":"ZSAN"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-03-02T19:07:14.000Z","date":"2018-01-02","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"As a result of a 1-for-20 reverse stock split of the common stock of the Company, which became effective at 5:00 p.m. Eastern Time on January 25, 2018 (the \"Reverse Split\"), the exercise price has increased from $0.53 per share to $10.60 per share."},{"field":"shares","element":"transactionShares","label":"F2","text":"As a result of the Reverse Split, the number of shares of the Company's common stock underlying the stock option has decreased from 30,000 shares to 1,500 shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the option shall vest on the first anniversary of the date of grant."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"As a result of the Reverse Split, the number of shares of the Company's common stock underlying the stock option has decreased from 30,000 shares to 1,500 shares."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"As a result of the Reverse Split, the number of shares of the Company's common stock underlying the stock option has decreased from 30,000 shares to 1,500 shares."}],"balance_after":30000,"derivative":{"exercise_price":0.53,"expiration_date":"2028-01-02","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001587221-18-000004","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000158722118000004/edgar.xml","form_type":"4"}},{"id":4105467,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-01-05T18:59:36.000Z","date":"2018-01-05","kind":"grant","acquired":true,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in forty-eight equal monthly installments, such that the option will be fully vested four years from the date of grant, subject to the Reporting Person's continuous service to us."}],"balance_after":1000000,"derivative":{"exercise_price":1.24,"expiration_date":"2028-01-04","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001209191-18-002557","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919118002557/doc4.xml","form_type":"4"}},{"id":4251869,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-07-25T18:08:18.000Z","date":"2017-07-25","kind":"purchase","acquired":true,"shares":219780,"price":0.91,"value":199999.8,"ownership":{"direct":true},"balance_after":241297,"source":{"system":"sec-edgar","filing":"0001209191-17-046233","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919117046233/doc4.xml","form_type":"4"}},{"id":4330024,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-05-08T16:26:41.000Z","date":"2017-05-04","kind":"grant","acquired":true,"shares":750000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares vest on May 4, 2018 and the remainder of the shares vest in equal installments on a monthly basis thereafter, such that the option is fully vested on May 4, 2021."}],"balance_after":750000,"derivative":{"exercise_price":1.7,"expiration_date":"2027-05-03","underlying":"Common Stock","underlying_shares":750000},"source":{"system":"sec-edgar","filing":"0001209191-17-030595","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919117030595/doc4.xml","form_type":"4"}},{"id":4427677,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-02-23T17:22:27.000Z","date":"2017-02-15","kind":"grant","acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares vest on January 1, 2018 and the remainder of the shares vest in equal installments on a monthly basis thereafter, such that the option is fully vested on January 1, 2021."}],"balance_after":160000,"derivative":{"exercise_price":1.2,"expiration_date":"2027-02-14","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001209191-17-013900","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919117013900/doc4.xml","form_type":"4"}},{"id":4473467,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-02-01T17:12:30.000Z","date":"2017-01-30","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On February 1, 2016, the reporting person was granted an option to purchase 30,000 shares of common stock. The option vests only upon achievement of a performance-based milestone. The performance criteria were met on January 30, 2017, resulting in vesting of the option. Upon achievement of the milestone, fifty percent of the shares immediately vest with the remaining shares vesting over the 24 month period following the vesting commencement date, subject to the reporting person's continuous service to Regulus."}],"balance_after":30000,"derivative":{"exercise_price":5.77,"exercise_date":"2017-01-30","expiration_date":"2026-01-31","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-17-006798","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919117006798/doc4.xml","form_type":"4"}},{"id":4566562,"issuer":{"id":12518,"kind":"organization","name":"Zosano Pharma Corp","symbol":"ZSAN"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2016-11-04T17:18:37.000Z","date":"2016-11-02","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option vest over one year in 12 equal monthly installments, beginning on November 1, 2016."}],"balance_after":20000,"derivative":{"exercise_price":0.575,"expiration_date":"2026-11-02","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-16-148475","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919116148475/doc4.xml","form_type":"4"}},{"id":4582525,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78041,"kind":"person","name":"Hagan Joseph P","position":1,"cik":"0001465278","reported_name":"Hagan Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2016-10-07T17:10:07.000Z","date":"2016-10-05","kind":"grant","acquired":true,"shares":59625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares vest on October 5, 2017 and the remainder of the shares vest in equal installments on a monthly basis thereafter, such that\nthe option is fully vested on October 5, 2021."}],"balance_after":59625,"derivative":{"exercise_price":3.52,"expiration_date":"2026-10-04","underlying":"Common Stock","underlying_shares":59625},"source":{"system":"sec-edgar","filing":"0001209191-16-145420","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465278/000120919116145420/doc4.xml","form_type":"4"}}]}